Adicet Bio, Inc.
ACET- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001720580
No open-market purchases or sales by Adicet Bio, Inc. insiders were filed in the last 90 days; 56 institutions reported holding it in 13F filings for Q2 2026, worth $52.8M in total; no superinvestor holds it.
Q3 2021 vs. Q2 2021
How the institutions holding Adicet Bio, Inc. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Of which not filed for Q3 2021 | Q3 2021 | Change |
|---|---|---|---|---|
| Holders | 66 | 1 | 58 | −7 |
| Shares | 21.2M | 728.9K | 19.9M | −578.8K (−2.8%) |
| Value | $218.1M | $7.50M | $156.1M | −$54.5M (−25.9%) |
1 institution that held it in Q2 2021 haven't filed for Q3 2021 yet. Not filing isn't selling, so the changes leave them out.
New holders (5)
Institutions that held Adicet Bio, Inc. at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Johnson & Johnson | 728,944 | $5.71M | 0.50% |
| Parametric Portfolio Associates LLC | 17,287 | $136.0K | 0.00% |
| SG Americas Securities, LLC | 14,655 | $115.0K | 0.00% |
| UBS Group AG | 152 | $1.00K | 0.00% |
| Ellevest, Inc. | 15 | $0 | 0.00% |
Sold out (12)
Institutions that held Adicet Bio, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Consonance Capital Management LP | 1,025,405 | $10.6M |
| Adage Capital Partners GP, L.L.C. | 488,000 | $5.02M |
| VR Adviser, LLC | 183,702 | $1.89M |
| Bridgeway Capital Management, LLC | 19,999 | $206.0K |
| Susquehanna International Group, LLP | 19,563 | $201.0K |
| Jump Financial, LLC | 13,300 | $137.0K |
| Marshall Wace, LLP | 12,545 | $129.0K |
| ProShare Advisors LLC | 11,141 | $115.0K |
| Acadian Asset Management LLC | 4,843 | $50.0K |
| STRS Ohio | 4,800 | $49.0K |
| Point72 Hong Kong Ltd | 1,735 | $18.0K |
| Panagora Asset Management Inc | 538 | $6.00K |
Not filed for Q3 2021 yet (1)
Institutions that held Adicet Bio, Inc. at the end of Q2 2021 and haven't filed a 13F for Q3 2021. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Johnson & Johnson Innovation - JJDC, Inc. | 728,944 | $7.50M |